FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2892557185> ?p ?o ?g. }

• W2892557185 endingPage "5" @default.
• W2892557185 startingPage "3" @default.
• W2892557185 abstract "GIPR signaling in adipose tissue plays an important role in HFD-induced insulin resistance and hepatic steatosis in vivo, with no direct effect on fat accumulation, through IL-6 signaling Obesity has been recognized as a worldwide problem, especially for developing insulin resistance and increasing the risk of type 2 diabetes. The increased adipose tissue associated with obesity secretes various kinds of cytokines, adipokines and lipokines, and triggers systemic inflammatory response, resulting in the disturbance of metabolic homeostasis. Gastric inhibitory polypeptide/glucose-dependent insulinotropic polypeptide (GIP) is an incretin secreted from enteroendocrine K cells in response to meal ingestion1, and potentiates insulin secretion through the GIP receptor (GIPR) expressed in pancreatic β-cells2. Dietary lipid is a very strong stimulant of GIP secretion. For example, the peak value of GIP increase in response to a high-fat meal (450 kcal containing 33.3% of fat) is threefold higher than that in the 75-g oral glucose tolerance test in human subjects, suggesting that fat content in a mixed meal strongly stimulates GIP secretion1. Chronic high-fat consumption induces hypersecretion of GIP from K cells3, and insulin secretion in response to GIP is enhanced in high-fat diet (HFD)-fed obese mice compared with that in lean mice fed a normal-fat diet4, indicating that GIPR signaling plays a critical role in postprandial hyperinsulinemia associated with chronic HFD feeding and the subsequent increase in lipoprotein lipase activity, which results in HFD-induced fat accumulation (Figure 1). Actually, reduction in GIPR signaling using systemic GIPR knockout (GIPR−/−) mice5, a GIP antagonist6 and GIP immunoneutralization ameliorates obesity under HFD-fed conditions. In addition, we have reported that genetic deletion of GIP alleviates obesity and lessens the degree of insulin resistance in HFD-fed mice7. In contrast, given that functional GIPR is expressed in rodent and human adipocytes, it has been assumed that GIP also has direct effects on adipose tissue and plays some roles in lipid metabolism under HFD-fed conditions. In vitro studies have shown that GIP directly induces fat accumulation in adipose tissue by increasing lipoprotein lipase expression through the cyclic adenosine monophosphate response element-binding protein (CREB)-regulated transcription coactivator 2-mediated pathway, and by increasing lipoprotein lipase enzyme activity and plasma membrane glucose transporter 4 expression through the protein kinase B (PKB)-mediated pathway8. However, the physiological significance of GIPR signaling in adipocytes, namely, whether GIPR expressed in adipose tissue plays some roles in HFD-induced obesity and insulin resistance in vivo, has remained unproven. To address this problem, we generated adipose tissue-specific GIPR knockout (GIPRadipo−/−) mice9. Under HFD-fed conditions, GIPRadipo−/− mice had significantly lower bodyweight and lean body mass compared with those in floxed GIPR (GIPRfl/fl) mice, although the fat volume was not significantly different between the two groups. Interestingly, insulin resistance, liver weight and hepatic steatosis were reduced in HFD-fed GIPRadipo−/− mice compared with those in GIPRfl/fl mice. Microarray analysis of adipose tissues showed that expression of interleukin-6 (IL-6), a pro-inflammatory cytokine that induces insulin resistance and hepatic steatosis10, was significantly decreased in adipose tissue of GIPRadipo−/− mice, and plasma levels of IL-6 were also reduced in HFD-fed GIPRadipo−/− mice compared with those in HFD-fed GIPRfl/fl mice. Previous in vitro studies have shown that GIP increases IL-6 expression levels in adipose tissue11. In astrocytes, CREB activated by β-adrenergic receptor enhances IL-6 expression induced by tumor necrosis factor (TNF)-α receptor signaling12. It has been reported that GIP activates CREB in adipose tissue13. In our study using differentiated 3T3-L1 adipocytes, IL-6 expression was significantly augmented by GIP in the presence of TNF-α, suggesting that GIP enhances IL-6 messenger ribonucleic acid (mRNA) expression induced by TNF-α in adipose tissue, possibly through CREB activation. Suppressor of cytokine signaling (SOCS) protein is induced by the activation of cytokine receptors, including the IL-6 receptor, TNF-α receptor and Toll-like receptors, and attenuates cytokine signal transduction14. Seven SOCS proteins have been identified, and SOCS1 and SOCS3 were recently reported to negatively regulate insulin signaling by competitively interfering with insulin receptor substrate binding to the insulin receptor15, by inhibiting insulin receptor autophosphorylation16 and by promoting proteasomal degradation of insulin receptor substrate17. In particular, SOCS3 signaling is located downstream of the IL-6 receptor14, and is associated with insulin resistance and hepatic steatosis18. Our in vitro experiments showed that GIP induced mRNA expression of IL-6 and SOCS3 in the presence of TNF-α in differentiated 3T3-L1 adipocytes. In addition, expression levels of SOCS3 mRNA were decreased in adipose and liver tissues of GIPRadipo−/− mice. These results suggest that a decrease in SOCS3 expression by GIPR deficiency might enhance insulin sensitivity and potentiate PKB phosphorylation in adipose and liver tissues. However, SOCS3 mRNA expression in skeletal muscle was not different between the two groups of mice, although PKB phosphorylation was increased in the skeletal muscle of GIPRadipo−/− mice. Further study is required to clarify the mechanism of the increase in insulin-induced PKB phosphorylation in the skeletal muscle of GIPR adipo−/− mice. It has also been reported that SOCS3 binds to the gene promoter of sterol regulatory element-binding protein-1c (SREBP-1c), which has critical roles in fat synthesis in the liver, and increases SREBP-1c mRNA expression18. Suppression of SOCS3 expression in db/db mice improves the hepatic steatosis through downregulation of SREBP-1c19. In our study, SREBP-1c and SOCS3 mRNA expression were decreased in the liver of HFD-fed GIPR adipo−/− mice, indicating that deletion of GIPR signaling in adipocytes results in the decrease in IL-6 production from adipose tissue and subsequent fat synthesis in the liver through the IL-6–SOCS3–SREBP-1c pathway. Although GIPR function in human adipose tissue is still unclear in vivo, in vitro study shows that GIP induces IL-6 mRNA expression and potentiates IL-6 secretion in the presence of TNF-α in human adipocytes11, which is consistent with our data showing that IL-6 mRNA expression is decreased in the adipocytes of HFD-fed GIPRadipo−/− mice. Based on the phenotypes of GIPRadipo−/− mice, it can be concluded that GIPR signaling in adipose tissue plays an important role in HFD-induced insulin resistance and hepatic steatosis in vivo, with no direct effect on fat accumulation, through IL-6 signaling (Figure 1). As shown above, there is sufficient evidence to confirm that GIP is an obesity-promoting factor in HFD conditions and that deletion of GIPR signaling causes resistance to diet-induced obesity. Additionally, we have reported that partial reduction of GIP alleviates obesity and lessens the degree of insulin resistance under HFD conditions7. These findings suggest that regulation of GIPR signaling, especially after fat intake, is a promising therapeutic approach to obesity and type 2 diabetes. GIP antagonism is one of the candidates for GIP-based treatment for diabetes and obesity. However, the results in mice are not necessarily recapitulated in humans. For example, previously developed (Pro3) GIP as a potent antagonist of GIPR in mice was shown to stimulate GIPR in humans20. In addition, given that GIPR is also expressed in various tissues, except for pancreatic β-cells and adipocytes, including the gastrointestinal tract, heart, inner layers of the adrenal cortex and several brain regions, further investigation is required to establish the systemic biological action of GIP before the implementation of GIPR antagonism as an anti-obesity/diabetes therapy to minimize unexpected adverse events. This study was supported by grants from the Ministry of Education, Culture, Sports, Science and Technology (MEXT); Japan Society for the Promotion of Science; Ministry of Health, Labor and Welfare; Ministry of Agriculture, Forestry and Fisheries; Japan Diabetes Foundation; Japan Association for Diabetes Education and Care; Merck Sharp & Dohme (MSD); Novo Nordisk Pharma; and Banyu Life Science Foundation International. The authors declare no conflict of interest." @default.
• W2892557185 created "2018-10-05" @default.
• W2892557185 creator A5049754800 @default.
• W2892557185 creator A5060317581 @default.
• W2892557185 date "2018-10-22" @default.
• W2892557185 modified "2023-10-18" @default.
• W2892557185 title "Gastric inhibitory polypeptide/glucose‐dependent insulinotropic polypeptide signaling in adipose tissue" @default.
• W2892557185 cites W1535257416 @default.
• W2892557185 cites W1582322448 @default.
• W2892557185 cites W1967717006 @default.
• W2892557185 cites W1979145580 @default.
• W2892557185 cites W1993418845 @default.
• W2892557185 cites W1995969505 @default.
• W2892557185 cites W1998002161 @default.
• W2892557185 cites W2032914675 @default.
• W2892557185 cites W2067902277 @default.
• W2892557185 cites W2080602135 @default.
• W2892557185 cites W2082213840 @default.
• W2892557185 cites W2102392334 @default.
• W2892557185 cites W2126393987 @default.
• W2892557185 cites W2131592975 @default.
• W2892557185 cites W2132198562 @default.
• W2892557185 cites W2135092079 @default.
• W2892557185 cites W2158860376 @default.
• W2892557185 cites W2159250215 @default.
• W2892557185 cites W2276372335 @default.
• W2892557185 cites W2577368877 @default.
• W2892557185 doi "https://doi.org/10.1111/jdi.12942" @default.
• W2892557185 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6319611" @default.
• W2892557185 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30248247" @default.
• W2892557185 hasPublicationYear "2018" @default.
• W2892557185 type Work @default.
• W2892557185 sameAs 2892557185 @default.
• W2892557185 citedByCount "7" @default.
• W2892557185 countsByYear W28925571852019 @default.
• W2892557185 countsByYear W28925571852020 @default.
• W2892557185 countsByYear W28925571852021 @default.
• W2892557185 countsByYear W28925571852022 @default.
• W2892557185 countsByYear W28925571852023 @default.
• W2892557185 crossrefType "journal-article" @default.
• W2892557185 hasAuthorship W2892557185A5049754800 @default.
• W2892557185 hasAuthorship W2892557185A5060317581 @default.
• W2892557185 hasBestOaLocation W28925571851 @default.
• W2892557185 hasConcept C126322002 @default.
• W2892557185 hasConcept C134018914 @default.
• W2892557185 hasConcept C17077164 @default.
• W2892557185 hasConcept C171089720 @default.
• W2892557185 hasConcept C2776129832 @default.
• W2892557185 hasConcept C2778563252 @default.
• W2892557185 hasConcept C2779306644 @default.
• W2892557185 hasConcept C555293320 @default.
• W2892557185 hasConcept C71924100 @default.
• W2892557185 hasConceptScore W2892557185C126322002 @default.
• W2892557185 hasConceptScore W2892557185C134018914 @default.
• W2892557185 hasConceptScore W2892557185C17077164 @default.
• W2892557185 hasConceptScore W2892557185C171089720 @default.
• W2892557185 hasConceptScore W2892557185C2776129832 @default.
• W2892557185 hasConceptScore W2892557185C2778563252 @default.
• W2892557185 hasConceptScore W2892557185C2779306644 @default.
• W2892557185 hasConceptScore W2892557185C555293320 @default.
• W2892557185 hasConceptScore W2892557185C71924100 @default.
• W2892557185 hasFunder F4320310023 @default.
• W2892557185 hasFunder F4320320912 @default.
• W2892557185 hasFunder F4320322266 @default.
• W2892557185 hasFunder F4320332932 @default.
• W2892557185 hasFunder F4320334764 @default.
• W2892557185 hasIssue "1" @default.
• W2892557185 hasLocation W28925571851 @default.
• W2892557185 hasLocation W28925571852 @default.
• W2892557185 hasLocation W28925571853 @default.
• W2892557185 hasLocation W28925571854 @default.
• W2892557185 hasLocation W28925571855 @default.
• W2892557185 hasOpenAccess W2892557185 @default.
• W2892557185 hasPrimaryLocation W28925571851 @default.
• W2892557185 hasRelatedWork W2046838521 @default.
• W2892557185 hasRelatedWork W2086466242 @default.
• W2892557185 hasRelatedWork W2094262609 @default.
• W2892557185 hasRelatedWork W2143040158 @default.
• W2892557185 hasRelatedWork W2157068658 @default.
• W2892557185 hasRelatedWork W2401628417 @default.
• W2892557185 hasRelatedWork W2414819670 @default.
• W2892557185 hasRelatedWork W2748952813 @default.
• W2892557185 hasRelatedWork W2948948335 @default.
• W2892557185 hasRelatedWork W3003972117 @default.
• W2892557185 hasVolume "10" @default.
• W2892557185 isParatext "false" @default.
• W2892557185 isRetracted "false" @default.
• W2892557185 magId "2892557185" @default.
• W2892557185 workType "article" @default.